Ionis Pharmaceuticals (IONS)
44.91
-0.49 (1.08%)
Upcoming Events
Latest Headlines
FDA approves GSK's Hibsago for chronic hepatitis B treatment
October 21, 2026 6:11 AM - StreetInsider
Citi defending Ionis Pharmaceuticals
October 21, 2026 4:08 AM - StreetInsider
Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)
October 20, 2026 9:20 PM - BizWire
Ionis Pharmaceuticals (IONS) PT Lowered to $79 at Raymond James
October 20, 2026 6:35 AM - StreetInsider
Form 4 IONIS PHARMACEUTICALS For: Oct 15 Filed by: Devers Shannon L.
October 19, 2026 9:40 PM - SEC Filing
Form 4 IONIS PHARMACEUTICALS For: Oct 15 Filed by: Swayze Eric
October 19, 2026 9:40 PM - SEC Filing
Form 144 IONIS PHARMACEUTICALS Filed by: Devers Shannon L.
October 16, 2026 5:17 PM - SEC Filing
EU panel recommends Ionis olezarsen for severe hypertriglyceridemia
October 16, 2026 6:45 AM - StreetInsider
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)
October 16, 2026 6:45 AM - BizWire
H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
September 24, 2026 6:45 AM - StreetInsider
Oppenheimer Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
September 24, 2026 5:41 AM - StreetInsider
BMO Capital Reiterates Market Perform Rating on Ionis Pharmaceuticals (IONS)
September 23, 2026 8:56 AM - StreetInsider
Canaccord Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
September 23, 2026 6:39 AM - StreetInsider
Form 8-K IONIS PHARMACEUTICALS For: Sep 23
September 23, 2026 6:04 AM - SEC Filing
Roche's sefaxersen meets Phase 3 primary endpoint in kidney disease trial
September 23, 2026 1:01 AM - StreetInsider
Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
September 23, 2026 1:00 AM - BizWire
Ionis Pharmaceuticals (IONS) PT Lowered to $70 at JPMorgan Amid Negative Sentiment
September 22, 2026 8:36 AM - StreetInsider
Ionis drug ulefnersen meets primary endpoint in FUS-ALS Phase 3 trial
September 22, 2026 8:01 AM - StreetInsider
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
September 22, 2026 8:00 AM - BizWire
Ionis Pharmaceuticals (IONS) PT Lowered to $80 at Guggenheim
September 15, 2026 6:58 AM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Lowered to $56 at Goldman Sachs
September 14, 2026 7:52 AM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Lowered to $85 at Barclays
September 9, 2026 5:06 AM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Lowered to $84 at Raymond James
September 8, 2026 12:43 PM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Lowered to $104 at Morgan Stanley
September 8, 2026 8:15 AM - StreetInsider
Needham Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
September 8, 2026 7:30 AM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Lowered to $85 at Canaccord
September 8, 2026 7:28 AM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Lowered to $54 at BMO Capital Post Pelacarsen Failure
September 8, 2026 7:26 AM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Lowered to $56 at Goldman Sachs
September 8, 2026 7:22 AM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Lowered to $100 at H.C. Wainwright
September 8, 2026 6:16 AM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Raised to $61 at BMO Capital
September 4, 2026 7:41 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
September 4, 2026 6:44 AM - StreetInsider
FDA approves Ionis Pharma's therapy to treat rare genetic disorder
September 3, 2026 4:03 PM - StreetInsider
FDA approves first treatment for Alexander disease
September 3, 2026 3:52 PM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
August 31, 2026 6:50 AM - StreetInsider
JPMorgan Reiterates Overweight Rating on Ionis Pharmaceuticals (IONS)
August 31, 2026 2:41 AM - StreetInsider
Alnylam stock drops on rival heart trial: Why analysts see core business safe
August 28, 2026 8:25 AM - StreetInsider
Canaccord Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
August 24, 2026 6:40 AM - StreetInsider
Ionis to present olezarsen and ION775 data at ESC Congress 2026
August 20, 2026 7:00 AM - StreetInsider
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
August 20, 2026 7:00 AM - BizWire
BMO Capital Starts Ionis Pharmaceuticals (IONS) at Market Perform
August 18, 2026 4:13 PM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Raised to $76 at JPMorgan
August 3, 2026 7:51 AM - StreetInsider
Form 4 IONIS PHARMACEUTICALS For: Jul 30 Filed by: Hayden Michael R
July 31, 2026 4:43 PM - SEC Filing
Form S-8 IONIS PHARMACEUTICALS
July 31, 2026 1:58 PM - SEC Filing
Ionis Pharmaceuticals (IONS) PT Lowered to $95 at Wells Fargo
July 30, 2026 8:35 AM - StreetInsider
Ionis Pharmaceuticals (IONS) PT Lowered to $115 at H.C. Wainwright
July 30, 2026 6:45 AM - StreetInsider
Form 10-Q IONIS PHARMACEUTICALS For: Jun 30
July 29, 2026 5:06 PM - SEC Filing
Form 8-K IONIS PHARMACEUTICALS For: Jul 29
July 29, 2026 7:31 AM - SEC Filing
Ionis Pharmaceuticals (IONS) Tops Q2 EPS by 37c
July 29, 2026 7:20 AM - StreetInsider
Ionis Pharmaceuticals chief scientific officer to retire in 2027
July 29, 2026 7:05 AM - StreetInsider
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire
July 29, 2026 7:05 AM - BizWire
Ionis reports second quarter 2026 financial results and highlights progress on key programs
July 29, 2026 7:00 AM - BizWire
H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
July 23, 2026 7:11 AM - StreetInsider
Canaccord Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
July 23, 2026 7:09 AM - StreetInsider
Full Article List
